SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)–positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer. Given the need to better understand the molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual, Tomás, Oliveira, Mafalda, Ciruelos, Eva, Bellet Ezquerra, Meritxell, Saura, Cristina, Gavilá, Joaquin, Pernas, Sonia, Muñoz, Montserrat, Vidal, Maria J., Margelí Vila, Mireia, Cejalvo, Juan M., González-Farré, Blanca, Espinosa-Bravo, Martin, Cruz, Josefina, Salvador-Bofill, Francisco Javier, Guerra, Juan Antonio, Luna Barrera, Ana María, Arumi de Dios, Miriam, Esker, Stephen, Fan, Pang-Dian, Martínez-Sáez, Olga, Villacampa, Guillermo, Paré, Laia, Ferrero-Cafiero, Juan M., Villagrasa, Patricia, Prat, Aleix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103897/
https://www.ncbi.nlm.nih.gov/pubmed/33968735
http://dx.doi.org/10.3389/fonc.2021.638482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103897/
https://www.ncbi.nlm.nih.gov/pubmed/33968735
http://dx.doi.org/10.3389/fonc.2021.638482

Ejemplares similares